Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
6.58
+0.34 (5.54%)
At close: Feb 13, 2026, 4:00 PM EST
6.60
+0.02 (0.38%)
After-hours: Feb 13, 2026, 4:10 PM EST
Profound Medical Revenue
Profound Medical had revenue of $5.29M in the quarter ending September 30, 2025, with 86.76% growth. This brings the company's revenue in the last twelve months to $14.30M, up 67.94% year-over-year. In the year 2024, Profound Medical had annual revenue of $10.68M with 48.35% growth.
Revenue (ttm)
$14.30M
Revenue Growth
+67.94%
P/S Ratio
16.59
Revenue / Employee
$100,683
Employees
142
Market Cap
237.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.68M | 3.48M | 48.35% |
| Dec 31, 2023 | 7.20M | 518.00K | 7.75% |
| Dec 31, 2022 | 6.68M | -192.00K | -2.79% |
| Dec 31, 2021 | 6.87M | -431.00K | -5.90% |
| Dec 31, 2020 | 7.30M | 3.13M | 74.99% |
| Dec 31, 2019 | 4.17M | 2.26M | 117.58% |
| Dec 31, 2018 | 1.92M | -1.98M | -50.81% |
| Dec 31, 2017 | 3.90M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Quanterix | 130.20M |
| Owlet | 99.64M |
| Sight Sciences | 76.05M |
| Electromed | 68.86M |
| 908 Devices | 65.05M |
| SANUWAVE Health | 41.28M |
| TriSalus Life Sciences | 40.21M |
| Senseonics Holdings | 29.30M |
PROF News
- 5 weeks ago - Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case - GlobeNewsWire
- 6 weeks ago - Profound Medical Corp. Announces Closing of Private Placement - GlobeNewsWire
- 7 weeks ago - Profound Medical Corp. Announces Upsize of Private Placement - GlobeNewsWire
- 7 weeks ago - Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th - GlobeNewsWire
- 2 months ago - Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement - GlobeNewsWire
- 2 months ago - Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation - GlobeNewsWire
- 2 months ago - Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings - GlobeNewsWire
- 3 months ago - Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease - GlobeNewsWire